中药注射剂联合多西他赛与顺铂治疗非小细胞肺癌的网状Meta分析
该网状Meta分析纳入85项随机对照试验、共6580例非小细胞肺癌患者,比较11种中药注射剂联合多西他赛与顺铂(DP)方案与单用DP的疗效与安全性,采用OR和SUCRA排序,显示联合方案优于单用DP,不同注射剂在提高缓解率、生活质量及免疫功能指标上各有优势。
要点
- 中药注射剂联合DP方案在非小细胞肺癌中总体优于单用DP。
- 黄芪注射液联合DP对提高缓解率SUCRA最高(90.25%)。
- 参附注射液联合DP对提升CD3+和CD4+的SUCRA最高。
核心结论
- 中药注射剂联合DP方案在非小细胞肺癌患者中优于单用DP方案。
- 黄芪注射液联合DP、鸦胆子油乳注射液联合DP、参附注射液联合DP、康莱特注射液联合DP等方案均显示显著疗效。
- 仍需多中心、设计良好的随机对照试验验证上述发现。
研究设计与样本
- 研究为网状Meta分析,检索多个数据库至2023年4月30日的随机对照试验。
- 纳入85项符合标准且方法学质量良好的随机对照试验,共6580例患者,涉及11种中药注射剂。
- 采用Stata 15.0和R 4.2.1软件分析,效应量为比值比(OR),用累积排序曲线下面积(SUCRA)排序。
主要发现
- 黄芪注射液联合DP在提高缓解率方面最有效(SUCRA:90.25%)。
- 鸦胆子油乳注射液联合DP在改善生活质量方面最有效(SUCRA:76.89%)。
- 参附注射液联合DP在提升CD3+和CD4+方面最有效(SUCRA分别为93.75%、88.50%)。
- 康莱特注射液联合DP在提升CD8+方面最有效(SUCRA:88.96%)。
- 鸦胆子油乳注射液联合DP在提升CD4+/CD8+方面最有效(SUCRA:93.13%)。
关键数值与推荐
- 纳入随机对照试验共85项,患者6580例,中药注射剂11种。
- 黄芪注射液联合DP提高缓解率的SUCRA为90.25%。
- 鸦胆子油乳注射液联合DP改善生活质量的SUCRA为76.89%。
- 参附注射液联合DP提升CD3+和CD4+的SUCRA分别为93.75%和88.50%。
- 康莱特注射液联合DP提升CD8+的SUCRA为88.96%,鸦胆子油乳注射液联合DP提升CD4+/CD8+的SUCRA为93.13%。
临床怎么用
- 临床可考虑在非小细胞肺癌DP化疗基础上联合中药注射剂以改善疗效。
- 提高缓解率可优先考虑黄芪注射液联合DP方案。
- 改善生活质量可优先考虑鸦胆子油乳注射液联合DP方案。
- 改善免疫功能可考虑参附注射液、康莱特注射液或鸦胆子油乳注射液联合DP方案。
局限性
- 结论需进一步多中心、设计良好的随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Non-small cell lung cancer (NSCLC) poses a serious threat to human health. Several clinical studies have reported the benefits of Chinese herbal injections (CHIs) in combination with docetaxel and cisplatin (DP). This multidimensional network meta-analysis aimed to investigate the preferred regimen of CHIs in combination with DP for the treatment of NSCLC. Methods: Multiple databases were searched to identify randomized controlled trials (RCTs) of CHIs for NSCLC from the database inception to 30 April 2023. Studies that met the inclusion criteria and exhibited good methodological quality were included. Data analysis was conducted using Stata 15.0 and R 4.2.1 software. An odds ratio (OR) was used as the effect size, and the surface under the cumulative ranking curve (SCURA) was employed to rank the evaluated treatments. Results: The network meta-analysis included 85 eligible RCTs, encompassing 6,580 patients and 11 CHIs. Astragalus Injection combined with DP was identified as the most effective regimen for improving the response rate (SUCRAs: 90.25%). Brucea Javanica Oil Milk Injection combined with DP proved most effective in ameliorating the quality of life (SUCRAs: 76.89%). Shenfu Injection combined with DP emerged as the most effective for enhancing CD3+ and CD4+ (SUCRAs: 93.75%, 88.50%). Kanglaite Injection combined with DP exhibited the best efficacy in improving CD8+ (SUCRAs: 88.96%). Brucea Javanica Oil Milk Injection combined with DP was the most potent regimen for enhancing CD4+/CD8+ (SUCRAs: 93.13%). Conclusion: CHIs in combination with DP outperformed DP alone in NSCLC patients. Astragalus Injection plus DP, Brucea Javanica Oil Milk Injection plus DP, Shenfu Injection plus DP, Kanglaite Injection plus DP, and Brucea Javanica Oil Milk Injection plus DP were significantly effective. However, further multicenter and well-designed RCTs are required to validate our findings.
引用
- Wen L, Xie L, Gong F, et al. Efficacy and safety of Chinese medicine injections in combination with docetaxel and cisplatin for non-small cell lung cancer: a network meta-analysis. Front Pharmacol. 2023. PMID: 38146464. doi:10.3389/fphar.2023.1277284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。